Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
December 03, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
October 30, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
October 17, 2024 08:00 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
October 07, 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
August 23, 2024 16:30 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
August 14, 2024 16:35 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 08, 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.